Literature DB >> 8905309

Epidemiology of Lyme disease in France: Lyme borreliosis in the region of Berry sud: a six year retrospective.

F Christiann1, P Rayet, O Patey, C Lafaix.   

Abstract

The purpose of this epidemiologic retrospective is to recognize the endemic nature of Lyme borreliosis in 'Berry', region of France. Fifty-nine cases have been reported here during the past six years (1988-1994). An erythema migrans (EM), or a late manifestation concurrent with positive ELISA-test represents the main inclusion criterion (case definition used by the CDC). The results reveal a high incidence considering the limited information available in France. The farmer has been found to be mainly at risk, with EM being observed in 49% of cases. In general, late manifestations are rarely described. Peripheral neurological manifestations occur more frequently than those reported in the USA. The steps taken as a result of our study of Lyme disease are in accordance with the recommendations of the World Health Organization.

Entities:  

Mesh：

Year:  1996        PMID： 8905309     DOI： 10.1007/bf00144000

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN： 0393-2990            Impact factor:   8.082


  10 in total

1.  Clinical manifestations of erythema chronicum migrans Afzelius in 161 patients. A comparison with Lyme disease.

Authors:  E Asbrink; I Olsson
Journal:  Acta Derm Venereol       Date:  1985       Impact factor: 4.437

Review 2.  Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis).

Authors:  E Asbrink; A Hovmark
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Solitary erythema migrans: a clinical, laboratory and epidemiological study of 77 Dutch patients.

Authors:  H Kuiper; I Cairo; A Van Dam; B De Jongh; T Ramselaar; L Spanjaard; J Dankert
Journal:  Br J Dermatol       Date:  1994-04       Impact factor: 9.302

Review 4.  Lyme disease.

Authors:  A C Steere
Journal:  N Engl J Med       Date:  1989-08-31       Impact factor: 91.245

5.  Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.

Authors:  G Baranton; D Postic; I Saint Girons; P Boerlin; J C Piffaretti; M Assous; P A Grimont
Journal:  Int J Syst Bacteriol       Date:  1992-07

6.  Epidemiology of borrelia infections in Austria.

Authors:  G Stanek; H Flamm; V Groh; A Hirschl; W Kristoferitsch; R Neumann; E Schmutzhard; G Wewalka
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-02

7.  Lyme carditis: cardiac abnormalities of Lyme disease.

Authors:  A C Steere; W P Batsford; M Weinberg; J Alexander; H J Berger; S Wolfson; S E Malawista
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

8.  Monoclonal antibodies for identification of Borrelia afzelii sp. nov. associated with late cutaneous manifestations of Lyme borreliosis.

Authors:  M M Canica; F Nato; L du Merle; J C Mazie; G Baranton; D Postic
Journal:  Scand J Infect Dis       Date:  1993

9.  The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis.

Authors:  A R Pachner; A C Steere
Journal:  Neurology       Date:  1985-01       Impact factor: 9.910

10.  An epidemiologic study of Lyme disease in southern Sweden.

Authors:  J Berglund; R Eitrem; K Ornstein; A Lindberg; A Ringér; H Elmrud; M Carlsson; A Runehagen; C Svanborg; R Norrby
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
  10 in total
  2 in total

Review 1.  Occupational risk of Lyme disease: an epidemiological review.

Authors:  J D Piacentino; B S Schwartz
Journal:  Occup Environ Med       Date:  2002-02       Impact factor: 4.402

2.  Endemic level of Lyme borreliosis in a region of central France: a sero-epidemiologic examination involving blood donors.

Authors:  F Christiann; P Rayet; D B Ngueodjibaye; O Patey; A Godefroy; J Klein; R Lapegue; J F Theron-Le Gargasson; E Godfroid; C Lafaix
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.